Facebook
Twitter
LinkedIn
Forward
10th Annual Updates from ASH 2024: Practice-Changing Abstracts
Chicago, IL US
February 28, 2025
Elevate Your Impact in Hematologic Oncology!
Join us for an event that unites community-based providers and academic oncologists, all dedicated to enhancing the care and outcomes of patients with hematologic malignancies. This activity will explore the latest treatment options and medical advancements aimed at reducing cancer-related deaths. You’ll gain insights into groundbreaking therapies like CAR T-cell therapy, novel immunotherapies, and targeted agents that represent the forefront of managing both newly diagnosed and relapsed blood cancers.
Stay informed with the latest scientific updates and innovative strategies that directly impact your practice. Participants will engage in discussions about rapidly evolving treatment landscapes, evaluate critical considerations for sequencing novel agents, and refine practice paradigms that elevate patient care across all treatment settings.
This is your chance to enhance your knowledge of best practices for treating hematologic cancers while learning when to refer patients for specialized quaternary care and clinical trial opportunities. Don’t miss out on this chance to stay ahead in your field—register today to secure your spot and transform your approach to patient management!
Learn more at the conference website!
Target Audience
This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.
Learning Objectives
After this activity, participants will be able to:
- Recall international trends in the care of hematologic malignancies;
- Identify the emerging treatment strategies, the role of targeted agents in therapeutic paradigms for patients with myeloid malignancies, and available clinical trial options and other approaches to patients with relapsed/refractory disease;
- State the optimal patient selection, timing, and regimens for stem cell transplantation with high-risk and relapsed/refractory disease;
- Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases including newly approved therapeutic classes;
- Discuss evolving treatment paradigms and therapy sequencing for novel agents in the care of patients with multiple myeloma, including approved and emerging CAR T-cell therapies, as well as bispecific antibodies with varied therapeutic targets;
- Illustrate how cutting-edge data presented at the 2024 Annual Meeting of the American Society of Hematology can apply to clinical practice;
- Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies and its place in evolving hematologic malignancy treatment standards;
- Evaluate the available treatments to care for patients with lymphoma based on optimal treatment sequencing, novel agents and their role in earlier lines of therapy, and how these change best practices for evidence-based care of both newly diagnosed and relapsed/refractory cases.
You may also be interested in
Time | Session | Faculty |
|---|---|---|
Pre-Conference | ||
7:30 am | Registration & Breakfast | |
7:45 am | Key Opinion Leader Breakfast | |
8:30 am | Allied Health Session | Emily Bauer, Alisa Heitman, Rachel Kraft |
9:30 am | Transition Break | |
9:35 am | Pharmacy Session: Toxicity Management | Kaitlin Kelly, PharmD, Sarvnaz Sadrameli, PharmD |
10:35 am | Break | |
Main Conference | ||
11:00 am | Welcome & Housekeeping Notes | |
11:05 am | Keynote: Cell Therapy | Katy Rezvani, MD, PhD |
12:00 pm | Lunch | |
1:00 pm | HL & NHL | Alexandra Rojek, MD |
1:30 pm | Updates in Myelofibrosis, MPN, MDS | Anand Patel, MD |
2:00 pm | Break | |
2:15 pm | Updates in AML | Rafael Madero-Marroquin, MD |
2:45 pm | Updates in Myeloma | Jennifer Cooperrider, MD |
3:15 pm | Break | |
3:30 pm | Bispecific Panel | Benjamin Derman, MD & Peter Riedell, MD |
4:00 pm | Updates in Cellular and Gene Therapy | Gregory Roloff, MD |
4:30 pm | Updates in Transplantation | Mariam Nawas, MD |
5:00 pm | Closing Remarks | Michael Bishop, MD |
5:10 pm | Reception | |
*The agenda is subject to change.
Convene
333 N Green Street
Chicago, IL
60607
United States
HYBRID CONFERENCE
Participants can participate in person or virtually. For more information, visit the conference website or contact Meeting Achievements via e-mail.
Convene at 333 North Green Street offers over 40,000 square feet of purpose-built meeting and event space for small to large programs. This property includes a dedicated meetings and events floor, sweeping views of downtown, optimal branding opportunities, and a unique design. The state-of-the-art meeting space is fully outfitted with seamless technology, an onsite AV team, and 5-star hospitality that will elevate your next meeting and event experience. Learn more at their website.
VISITING CHICAGO
Discover why Condé Nast Traveler readers voted Chicago the Best Big City in the U.S. for a historic eighth year in a row. To help plan your stay in Chicago, visit choosechicago.com.
ACCESSIBILITY The University of Chicago is committed to providing equal access appropriate to need and circumstances and complies fully with legal requirements of the Americans with Disabilities Act. If you are in need of special accommodation, please contact Meeting Achievements via email at tarah@meetingachievements.com.
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
UNIVERSITY OF CHICAGO COURSE DIRECTOR
Michael R. Bishop, MDProfessor of Medicine
Director, Jonas Center for Cellular Therapy
Director, Hematopoietic Stem Cell Transplantation Program
Disclosure Declarations
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.
Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
Participants who successfully complete the entire activity and complete an evaluation form will earn 6 contact hours.
American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Please Note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months will be subject to additional fees.
EXHIBIT OPPORTUNITIES ARE AVAILABLE! SPACE IS LIMITED, SO SIGN UP TODAY!
Don't miss this opportunity to place your company at the forefront of hematologic oncology innovation! By exhibiting at the 10th Annual Updates from ASH 2024, you will reach an exclusive audience of community-based clinicians, academic oncologists, and healthcare professionals deeply committed to advancing blood cancer treatment. Connect directly with key decision-makers eager to learn about cutting-edge therapies, breakthrough technologies, and impactful support solutions that enhance patient care.
Our exhibitor spaces are designed to maximize engagement, allowing you to showcase your products and services in dynamic interactions with physicians, hematologists, oncologists, nurse practitioners, physician assistants, pharmacists, and other specialists. Whether through one-on-one connections during breaks or prominent brand visibility in the event program, this conference provides a powerful platform to elevate your company’s profile, forge valuable relationships, and make a lasting impression in hematologic oncology.
Download the
prospectus or contact Tarah Hamby at support@meetingachievements.com or 219-465-1115 Ext. 107. We hope to see you there!
REGISTRATION
Early rates expire on January 17 and space is limited, so reserve your spot today!
Profession Type | In Person | Virtual |
|---|---|---|
Physicians | $100/$125 | $50/$60 |
Nurses, Pharmacists, Other Healthcare Professionals | $45/$60 | $30/$40 |
Residents & Fellows with a verification letter | $25 | $25 |
| UChicago Faculty & Staff | $25 | $0 |
| Industry | $495 | $195 |
CANCELLATION POLICY Please see the registration site for the full details. | ||
CLAIMING CREDIT
After creating an account or logging in, enter the access code to unlock the credit claiming process.
Please Note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months will be subject to additional fees.
Please Note: The credit claiming process will close three months after the activity ends. Requests to claim credit after three months will be subject to additional fees.
Please login or create an account to proceed.